Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope
Middle East North Africa
Mucorales
antifungal agents
fungal epidemiology
invasive fungal disease
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
17
03
2020
revised:
15
05
2020
accepted:
18
05
2020
pubmed:
3
6
2020
medline:
2
6
2021
entrez:
3
6
2020
Statut:
ppublish
Résumé
Regional differences in the underlying causes, manifestations and treatment of mucormycosis have been noted in studies covering Europe, Asia and South America. To review cases of mucormycosis across the Middle East and North Africa (MENA) region in order to identify epidemiological, treatment and outcome trends in this region. Cases of proven or probable invasive mucormycosis from the region were identified from the FungiScope We identified 310 cases of mucormycosis in the MENA region. The number of reported cases increased by decade from 23 before 1990 to 127 in the 2010s. In this region, the most common underlying conditions associated with mucormycosis were diabetes mellitus (49.7%) and conditions associated with immunosuppression (46.5%). The majority of patients received treatment with antifungals (93.5%), with a large proportion treated with both antifungals and surgery (70.6%). Overall mortality rates decreased from 47.8% before 1990 to 32.3% in the 2010s. The number of reported cases of mucormycosis in the MENA region has risen over the past few decades, in line with increases in the number of patients with underlying conditions associated with this infection. Although the majority of patients received treatment with antifungal therapies and/or surgery, the associated mortality rate remains high and there is a clear need for more effective prevention and treatment strategies in the MENA region.
Sections du résumé
BACKGROUND
BACKGROUND
Regional differences in the underlying causes, manifestations and treatment of mucormycosis have been noted in studies covering Europe, Asia and South America.
OBJECTIVES
OBJECTIVE
To review cases of mucormycosis across the Middle East and North Africa (MENA) region in order to identify epidemiological, treatment and outcome trends in this region.
PATIENTS/METHODS
METHODS
Cases of proven or probable invasive mucormycosis from the region were identified from the FungiScope
RESULTS
RESULTS
We identified 310 cases of mucormycosis in the MENA region. The number of reported cases increased by decade from 23 before 1990 to 127 in the 2010s. In this region, the most common underlying conditions associated with mucormycosis were diabetes mellitus (49.7%) and conditions associated with immunosuppression (46.5%). The majority of patients received treatment with antifungals (93.5%), with a large proportion treated with both antifungals and surgery (70.6%). Overall mortality rates decreased from 47.8% before 1990 to 32.3% in the 2010s.
CONCLUSIONS
CONCLUSIONS
The number of reported cases of mucormycosis in the MENA region has risen over the past few decades, in line with increases in the number of patients with underlying conditions associated with this infection. Although the majority of patients received treatment with antifungal therapies and/or surgery, the associated mortality rate remains high and there is a clear need for more effective prevention and treatment strategies in the MENA region.
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
1060-1068Subventions
Organisme : Basilea Pharmaceutica International Ltd.
ID : 2#102273
Informations de copyright
© 2020 Wiley-VCH GmbH.
Références
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421.
Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26-34.
Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5(1):26.
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23-S34.
Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859-1867.
Bitar D, Lortholary O, Le Strat Y, et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis. 2014;20(7):1149-1155.
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-653.
NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513-1530.
Low CY, Rotstein C. Emerging fungal infections in immunocompromised patients. F1000 Med Rep. 2011;3:14.
Salmanton-García J, Seidel D, Koehler P, et al. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). J Antimicrob Chemother. 2019;74(11):3315-3327.
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828-837.
Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the mold: a review of mucormycosis and current pharmacological treatment options. Ann Pharmacother. 2016;50(9):747-757.
Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-569.
Sivagnanam S, Sengupta DJ, Hoogestraat D, et al. Seasonal clustering of sinopulmonary mucormycosis in patients with hematologic malignancies at a large comprehensive cancer center. Antimicrob Resist Infect Control. 2017;6:123.
Talmi YP, Goldschmied-Reouven A, Bakon M, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg. 2002;127(1):22-31.
Nucci M, Engelhardt M, Hamed K. Mucormycosis in South America: a review of 143 reported cases. Mycoses. 2019;62(9):730-738.
Rüping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2010;65(2):296-302.
FungiScope®. Global Emerging Fungal Infection Registry. http://www.fungiscope.net/. Accessed March 9, 2020.
Seidel D, Durán Graeff LA, Vehreschild M, et al. FungiScope® -Global Emerging Fungal Infection Registry. Mycoses. 2017;60(8):508-516.
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases. 2019;ciz1008. https://academic.oup.com/cid/article/doi/10.1093/cid/ciz1008/5645434#186464855
Cornely OA, Hoenigl M, Lass-Florl C, et al. Defining breakthrough invasive fungal infection-Position paper of the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology. Mycoses. 2019;62(9):716-729.
El-Mahallawy HA, Khedr R, Taha H, Shalaby L, Mostafa A. Investigation and management of a Rhizomucor outbreak in a pediatric cancer hospital in Egypt. Pediatr Blood Cancer. 2016;63(1):171-173.
Pagano L, Valentini CG, Posteraro B, et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana Animale and European Confederation of Medical Mycology). J Chemother. 2009;21(3):322-329.
Chander J, Kaur M, Singla N, et al. Mucormycosis: battle with the deadly enemy over a five-year period in India. J Fungi (Basel). 2018;4(2):46.
Bhatkar S, Goyal MK, Takkar A, et al. Cavernous sinus syndrome: a prospective study of 73 cases at a tertiary care centre in Northern India. Clin Neurol Neurosurg. 2017;155:63-69.
Heimann SM, Vehreschild M, Cornely OA, et al. Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016. J Hosp Infect. 2019;101(3):339-346.
Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis. 2012;54(Suppl 1):S35-S43.
Sherif S, Sumpio BE. Economic development and diabetes prevalence in MENA countries: Egypt and Saudi Arabia comparison. World J Diabetes. 2015;6(2):304-311.
Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-281.
Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56(Suppl 1):93-101.
Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127-e130.
Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol. 2019;57(4):395-402.
Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5-26.